Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec Receives Boehringer Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Evotec Receives Boehringer Milestone

Backup compound hits Phase I

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Evotec AG has received a milestone payment of $2.8 million from Boehringer Ingelheim after a back-up compound in their strategic alliance advanced into a Phase I trial. The compound, which was discovered and optimized within the alliance, is being developed as a novel treatment for neuropathic pain.

The alliance has involved working on multiple high priority targets across key therapeutic areas. So far it has resulted in 13 milestone payments from multiple programs. Dr Werner Lanthaler, chief executive officer of Evotec, remarked, “New more effective treatments against pain are urgently needed. We continue to enjoy a rewarding partnership at both scientific and commercial levels with Boehringer Ingelheim.”

The companies began their collaboration In 2004, to jointly identify and develop preclinical development candidates for the treatment of various disease areas including CNS, inflammation, cardiometabolic and respiratory diseases. In 2009, the collaboration was extended for an additional four years and the scope expanded to include oncology targets. BI has full ownership and global responsibility for clinical development, manufacturing and commercialization of the compounds identified. In return, Evotec receives ongoing research payments and preclinical milestones. The contract also provides substantial long-term upside for Evotec through potential payments for successful milestone achievements during clinical development and royalties when new drugs reach the market.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters